Retinal and choroidal conditions are the leading cause of severe vision loss worldwide [1]. The choice of first and second-intention drugs depends on the condition being addressed. As for neovascular age-related macular degeneration (nAMD), it was reported that Bevacizumab is the most preferred first intention due to its low economic burden [2]. However, due to the fact that it is off-label, Ranibizumab and Aflibercept became a popular therapeutic option among specialists [3], [4]. In diabetic macular oedema (DMO), Aflibercept is the first intention choice while Dexamethasone intravitreal implant represents the second one [5], [6]. In cases of retinal vein occlusion (RVO), clinicians tend to select Aflibercept as a first choice due to its therapy's beneficial patient outcomes. The reduced treatment burden associated with Dexamethasone intravitreal implant makes it the commonly used second intention choice [7]. Ranibizumab and Aflibercept are alternatively used as first or second intention since both are associated with increased visual acuity outcomes [8]. Therefore, their use in retinal conditions largely depends on clinician preference [9]. Although anti-VEGF therapy has become the standard treatment for retinal and choroidal vascular conditions, research on individual treatment agents is still in progress [10]. Numerous researchers have evaluated the pharmacokinetic and pharmacodynamic properties of several drugs and their efficacy which has informed decision making in clinical settings. The uncertainty as to which agents should be used as first or second intention remains and clinicians base their decisions on facts presented in the research literature, the disease prognosis, and individual experiences which may result in over or under treatment of patients. Furthermore, little is known about which therapeutic agent physicians use if they would themselves be diagnosed with the above-mentioned ocular conditions [11]. The literature being scarce on the subject, this study aims to fill this gap by providing the therapeutic agents that can be used solely as first or second intention in clinical settings. The study also aims at determining if there is a discordance between the treatments that ophthalmologists prescribe for themselves and those prescribed to their patients. The distinction between agents to be used as the first or second intention is hypothesized to reduce persistence and recurrence, which improves patient satisfaction while reducing treatment burden. Furthermore, with emergence of biosimilars drugs, the perception and intend-to-treat with these molecules remains uncertain. The aim of the present study was to define the preferred first intention and switch drugs for nAMD, DMO, RVO and myopic maculopathy with choroidal neovascularization (MMCN) when ophthalmologists prescribe for patients versus when they do so for themselves.